ARQT Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

$17.49  +0.41 (2.40%)
As of 12/02/2022 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2020
Outstanding shares:  60,927,824
Average volume:  866,315
Market cap:   $1,040,647,234
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKX9VD3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.54
PS ratio:   0.00
Return on equity:   -92.46%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy